FDA's Pulmonary-Allergy Drugs Advisory Committee
Executive Summary
Will meet April 26 to discuss NDAs for Pfizer's less-sedating antihistamine Zyrtec (cetirizine) and Burroughs-Wellcome's combination treatment for allergic rhinitis Semprex-D (acrivastine and pseudoephedrine). The meeting begins at 8 a.m. in Parklawn building conference rooms D & E.